APRIL HURLEY: Open Payments
NPI 1427489640 · MANCHESTER, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$381 in 20 payments from 10 companies in 2025. Trend: 2023 $438 · 2024 $430 · 2025 $381
Food & beverage: $381
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 5 | $111 |
| Novo Nordisk Inc | 3 | $53 |
| Lilly USA, LLC | 3 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| Medtronic, Inc. | 1 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Biogen, Inc. | 1 | $27 |
| ABBVIE INC. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Neurocrine BioSciences, Inc. | 1 | $14 |
Products named: HETLIOZ, MOUNJARO, Rybelsus, CAPLYTA, ENDURANT IIS, REXULTI, ZURZUVAE, QULIPTA.
Industry payments across KY — which companies pay providers there.
